Claudio Bordignon - MolMed S Insider

MolMed S p A -- Germany Stock  

EUR 0.38  0.01  2.56%

Chairman of the Board, CEO

Prof. Claudio Bordignon serves as Chairman of the Board of Molecular Medicine S.p.A. since November 6, 2007. He was also Chief Executive Officer at the firm from November 6, 2007 to December 11, 2015. He also acts as the Chairman of the Scientific Advisory Board of the Company. He is Founder of the Company and Pioneer in genetic and molecular therapy. He has produced publications and holds several patents in this field, which constitute one of the parts of the intellectual property of Molecular Medicine SpA. He headed the genetic therapy program and the bone marrow transplant unit of Istituto Scientifico San Raffaele, where he previously served as Scientific Director. In July 2005, he was Founding Member of the Scientific Board of the European Research Council. He is Professor of Hematology at the Medicine Faculty of Universita VitaSalute San Raffaele di Milano. He gained a Doctorate of Medicine in Medicine from the Universita degli Studi di Milano and conducted studies and research in various institutions in the United Sates.
Age: 66  Chairman Since 2015  Ph.D    

Management Efficiency

The company has return on total asset (ROA) of (18.1) % which means that it has lost $18.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (61.21) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 964 K in total debt with debt to equity ratio (D/E) of 6.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. MolMed S p A has Current Ratio of 1.37 which is within standard range for the sector.

Similar Executives

Entity Summary

MolMed S p A (4HW) is traded on Frankfurt Stock Exchange in Germany. and employs 23 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add MolMed S p A to your portfolio

Top Management

MolMed S p Leadership Team
Gian Rizzardi, Director, Ph.D
Marina Bue, Director
Didier Trono, Director
Silvia Pisante, Executive
Mario Masciocchi, Director
Carlo Incerti, Director
Raffaella Ruggiero, Director
Holger Neecke, Director
Luca Alberici, Executive
Maurizio Tassi, Director
Daniele Pieraccioli, Director, Ph.D
Alberto Carletti, Director
Laura Ferro, Director
Marco Dieci, Director, Ph.D
Catia Traversari, Director, Ph.D
Lorenzo Salieri, Director
Elizabeth Robinson, Director
Riccardo Palmisano, CEO
Sabina Grossi, Director, Ph.D
Alfredo Messina, Director
Monica Masolo, Director
Germano Carganico, Executive, Ph.D
Claudio Bordignon, Chairman, Ph.D
Gianluigi Fiorendi, Director
Andrea Quaglino, Director
Khalid Islam, Director, Ph.D
Laura Villa, Director
Cynthia Giuliani, Director
Antonio Lambiase, Director, Ph.D
Marco Manoni, Director
Tiziano Andreoli, Director

Stock Performance

MolMed S Performance Indicators